Stanford is running 37,000 AI agents as a virtual biotech — and one of its drug designs got independently confirmed by Merck
For developers, the operating assumption has been one engineer, one agent — the model Claude Code and similar tools. At VB Transform 2026, James Zou, associate professor of biomedical data science at Stanford University, argued that assumption is about to break: the next frontier isn't a single, more capable agent, it's tens of thousands of them collaborating. For developers and product builders, the most critical takeaway from Zou’s presentation is how these massive systems are orchestrated. His team's research offers a practical blueprint for connecting legacy databases to AI orchestration layers and designing environments that enable thousands of agents to collaborate. Emulating the organization — the virtual biotech Zou’s project began as a "Virtual Lab" consisting of five to eight agents structured to mirror his physical Stanford lab. The setup included an AI professor acting as the principal investigator and AI students with distinct specialties holding regular group meetings. "We also created for the agents a replica of Stanford, an agent school, where the agents can actually go to the school and do supervised fine-tuning to improve their expertise in their specific domains," Zou noted. The virtual lab successfully designed new nanobody proteins for recent COVID variants. "What is really exciting to us is that these AI-designed nanobody proteins actually worked much better than the previous human-designed nanobodies in terms of binding to the recent different viruses," Zou said. Following this wet-lab validation, the team expanded their ambition. They transitioned from emulating a single research team to modeling a massive corporate structure. The resulting system, dubbed the Virtual Biotech, comprises tens of thousands of specialized AI agents overseen by a Ch
For developers, the operating assumption has been one engineer, one agent — the model Claude Code and similar tools. At VB Transform 2026, James Zou, associate professor of biomedical data science at Stanford University, argued that assumption is about to break: the next frontier isn't a single, more capable agent, it's tens of thousands of them collaborating. For developers and product builders, the most critical takeaway from Zou’s presentation is how these massive systems are orchestrated. His team's research offers a practical blueprint for connecting legacy databases to AI orchestration layers and designing environments that enable thousands of agents to collaborate. Emulating the organization — the virtual biotech Zou’s project began as a "Virtual Lab" consisting of five to eight agents structured to mirror his physical Stanford lab. The setup included an AI professor acting as the principal investigator and AI students with distinct specialties holding regular group meetings. "We also created for the agents a replica of Stanford, an agent school, where the agents can actually go to the school and do supervised fine-tuning to improve their expertise in their specific domains," Zou noted. The virtual lab successfully designed new nanobody proteins for recent COVID variants. "What is really exciting to us is that these AI-designed nanobody proteins actually worked much better than the previous human-designed nanobodies in terms of binding to the recent different viruses," Zou said. Following this wet-lab validation, the team expanded their ambition. They transitioned from emulating a single research team to modeling a massive corporate structure. The resulting system, dubbed the Virtual Biotech, comprises tens of thousands of specialized AI agents overseen by a Ch
